Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 15.59 as of 2026-09-11T10:20:29.679Z.
Consensus retrieved: 2026-09-10T23:31:38.145Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-09-11T10:20:29.679Z.
Quote observation: 2026-09-10T20:00:02.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 528d3ba9148e81a59322c16104731b7399dfc1101138210616e0d0efbf11ec7a
Forward PE Ratio (15.59) = Dated Quote Price ($159.64) / Consensus Forward EPS ($10.24)
FORWARD PE RATIO
15.59
SECTOR MEDIAN · HEALTHCARE
18.93
median of 76 covered companies
CURRENT VS SECTOR MEDIAN
-17.64%
vs the sector median at left
AstraZeneca PLC
Market Cap
$247.58B
Forward PE Ratio
15.59
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| AstraZeneca PLC (AZN) | $247.58B | 15.59 |
| Thermo Fisher Scientific Inc. (TMO)vs › | $224.15B | 24.02 |
| Amgen Inc. (AMGN)vs › | $206.42B | 16.57 |
| Novo Nordisk A/S (NVO)vs › | $195.43B | N/A |
| Gilead Sciences, Inc. (GILD)vs › | $179.79B | N/A |
| Abbott Laboratories (ABT)vs › | $178.87B | 18.74 |
| Pfizer Inc. (PFE)vs › | $157.59B | 9.30 |
| Roche Holding AG (RHHBY)vs › | $339.06B | N/A |
| UnitedHealth Group Incorporated (UNH)vs › | $352.61B | 19.65 |
| Danaher Corporation (DHR)vs › | $141.00B | 23.58 |
Trailing P/E
24.0
reported TTM EPS
Forward P/E
15.6
consensus EPS · fiscal year ending 2026-12-31
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $10.24 implies +53.8% EPS growth vs the reported trailing $6.66.
At the dated quote price of $159.64, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $10.24 | $5.68 – $11.26 | 7 | 15.6x |
| 2027-12-31 | $11.48 | $6.27 – $12.86 | 8 | 13.9x |
| 2028-12-31 | $12.79 | $9.70 – $14.04 | 11 | 12.5x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
